Quintiles announces strategic alliance with Movetis NV for commercialization of Resolor

Quintiles today announced a strategic alliance with Movetis NV for commercialization of its new product, Resolor (prucalopride), in the U.K. and Germany. Under the alliance, Quintiles will execute a comprehensive commercial sales effort for the product launch and provide additional services in consulting, market access, market intelligence and analytics, regulatory and post-marketing pharmacovigilance. The agreement is expected to be extended later this year to cover other selected European countries.

“We are confident that our alliance with Quintiles will help drive our goal of becoming a successful European specialty GI company. The launch of Resolor will be a key milestone as we continue to build on our expertise in bringing new GI drugs from discovery to marketing.”

Movetis is a European specialty pharmaceutical company focused on the discovery, development and commercialization of proprietary and innovative drugs for the treatment of diseases in the gastrointestinal (GI) area. Movetis obtained approval for the commercialization of Resolor in the European Economic Area for the symptomatic treatment of chronic constipation for women in whom laxatives fail to provide adequate relief.

Chris Pepler, Senior Vice President of Global Business Development and Operations for Quintiles said: “This agreement is an example of how leading specialty pharma companies are building partnerships that extend beyond the traditional Commercial Sales Organization model to manage risk, increase productivity, overcome complexity and demonstrate value to stakeholders in the New Health. We are pleased that Movetis has chosen to leverage Quintiles’ suite of comprehensive services, including our product and brand solutions, to help ensure the commercial success of Resolor.”

Movetis CEO Dirk Reyn said: “We are confident that our alliance with Quintiles will help drive our goal of becoming a successful European specialty GI company. The launch of Resolor will be a key milestone as we continue to build on our expertise in bringing new GI drugs from discovery to marketing.”

Source: Quintiles

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Quintiles. (2010, January 29). Quintiles announces strategic alliance with Movetis NV for commercialization of Resolor. News-Medical. Retrieved on September 20, 2021 from https://www.news-medical.net/news/20100129/Quintiles-announces-strategic-alliance-with-Movetis-NV-for-commercialization-of-Resolor.aspx.

  • MLA

    Quintiles. "Quintiles announces strategic alliance with Movetis NV for commercialization of Resolor". News-Medical. 20 September 2021. <https://www.news-medical.net/news/20100129/Quintiles-announces-strategic-alliance-with-Movetis-NV-for-commercialization-of-Resolor.aspx>.

  • Chicago

    Quintiles. "Quintiles announces strategic alliance with Movetis NV for commercialization of Resolor". News-Medical. https://www.news-medical.net/news/20100129/Quintiles-announces-strategic-alliance-with-Movetis-NV-for-commercialization-of-Resolor.aspx. (accessed September 20, 2021).

  • Harvard

    Quintiles. 2010. Quintiles announces strategic alliance with Movetis NV for commercialization of Resolor. News-Medical, viewed 20 September 2021, https://www.news-medical.net/news/20100129/Quintiles-announces-strategic-alliance-with-Movetis-NV-for-commercialization-of-Resolor.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Quintiles' growth in service revenues increases 7.7% in Q4 2013